adh-1-pepide and Neoplasms

adh-1-pepide has been researched along with Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for adh-1-pepide and Neoplasms

Article	Year
Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization. Current opinion in molecular therapeutics, 2007, Volume: 9, Issue:1 Adherex Technologies Inc, under license from McGill University, is developing ADH-1, an intravenous N-cadherin antagonist that specifically disrupts the disorganized interactions between N-cadherin molecules in tumor blood vessels, as a potential anticancer compound. By May 2005, ADH-1 was in phase Ib/II clinical trials in Europe and the US, and phase II clinical trials in Canada. Topics: Angiogenesis Inhibitors; Animals; Cadherins; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Peptides, Cyclic	2007

Article

Year

Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.

Current opinion in molecular therapeutics, 2007, Volume: 9, Issue:1

Adherex Technologies Inc, under license from McGill University, is developing ADH-1, an intravenous N-cadherin antagonist that specifically disrupts the disorganized interactions between N-cadherin molecules in tumor blood vessels, as a potential anticancer compound. By May 2005, ADH-1 was in phase Ib/II clinical trials in Europe and the US, and phase II clinical trials in Canada.

Topics: Angiogenesis Inhibitors; Animals; Cadherins; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Peptides, Cyclic

2007